2. Lean Resources and Short Timelines

The analysis of the FDA CRLs show that 35% of rejections were issued due to deficiencies in clinical trials [1], with 19% requesting additional confirmatory trials, dosing regimen re-evaluation, highlighting quality and integrity findings at the clinical sites. 

Had there been expert CMC advice, it is possible that these deficiencies could have been avoided. Furthermore, resources could have been redirected to what matters – developing and progressing the technology to reach regulatory approval and, ultimately, the patients in need of new therapies. 

Consultants are indispensable in generating customized process development roadmaps, analytical strategy, appropriate timing for CRO/CDMO engagement, and product definition and specifics for the stages of development. When these early-stage design and oversight gaps are addressed, the financial and regulatory impact is measurable, and ROI becomes quite evident.

3. ROI and Cost of Delays

More than 40% of unsuccessful oncology IND filings were related to CMC problems, predominantly due to the sponsors’ limited regulatory experience. Based on the review published by the journal of Regulatory Toxicology and Pharmacology [2], it took on average 114 days to resolve these issues, with some cases requiring more than two years. 

The regulatory benefits of expert CMC guidance also have a direct financial dimension. A consultant’s ability to anticipate and resolve CMC issues raises the likelihood of a smooth regulatory review, which can help to preserve investor confidence by demonstrating disciplined execution and well-mapped timelines. 

Specific case studies, performed by several consulting agencies, show how companies that engaged professional consulting services shortened their timelines to IND by 1.5 years and improved the approval outcome by 23% [3]. In early- and mid-stage financing rounds, this operational credibility can be as critical as the underlying science in securing continued funding. Yet, ROI isn’t only about timelines and capital — the culture and operational habits within a company determine whether those gains are sustained.

4. Cultural Integration and Operational Efficiency

Small companies thrive on the innovative spirit and fast-moving pace of its people. They are driven by expanding the frontiers of known science tied with a passion to alleviate the suffering of people living with disease. Often, companies resort to engaging CRO/CDMO early in the process to establish operational abilities, so they can expand their process development and analytical development expertise. 

Despite the benefits of this approach, the lack of maturity of the product and technology, combined with the team’s lack of experience in management of outsourcing workflows can lead to longer timelines and cost overruns. Operational inefficiencies are cited as one of the major causes of the “valley of death” for many companies, contributing to the bleak success rate statistics for start-ups. 

Engaging external experienced consultants can lead to operational excellence [4], delivering on pre-clinical timelines, fostering speed and innovation, augmenting talent and core capabilities, and accelerating development.  

While specific overall IND approval rates solely due to consultants are complex to isolate in broad statistics, the overall data strongly suggests a significant increase in the operational efficiency and resulting quality of submissions. Experts also agree that in the critical pre-clinical phase leading up to First-in-Human (FIH) studies, companies employing optimized strategies (often guided by external expertise) have shown a capacity to reduce the IND timeline by 40% or more, enabling progression from candidate nomination to clinical trials in as little as 12 to 15 months [5] (McKinsey & Company). 

When you consider that clinical trial delays can equate to approximately $500,000 in lost sales per day [6], the investment in expert CMC consulting becomes not just beneficial, but a critical imperative. This combination of technical depth, operational maturity, and cultural fit positions companies to not only reach IND faster but to do so in a way that wins both: regulator trust and investor confidence. Ultimately, these benefits are most relevant to “accelerationists” — founders committed to strategic planning, robust CMC readiness, and operational excellence as levers to extend runway and build investor confidence.

Key Actionable Steps

Strategic CMC consulting is a critical investment that accelerates drug development and maximizes IND success. The following are the key actionable steps to identify and partner with the right expertise:

1. Look for Phase-Appropriate Expertise.
   Explore specifics from pre-clinical to early phase IND, familiarity with fast-track, orphan indications, and breakthrough therapies.
2. Prioritize Strong Analytical and CMC Foundations. 
   Critical aspects to look for include assay development, qualification and validation experience, establishing and justifying Critical Quality Attributes (CQA), technology transfer and management of CRO/CDMO, quality and data integrity and GxP expectations.
3. Regulatory Submission Experience. 
   Determine the extent of experience with FDA IND, EMA IMPD, and CTA submissions and fluency with ICH guidelines.
4. Assess Communication and Integration Skills. 
   These skills include clear communication, well-structured advice, and a strong ability to effectively collaborate with R&D, Quality Assurance, process scientists, and external partners.  Strong communication and integration skills lead to successful partnerships.
5. Look for Value-Driven Outcomes, Not Just Technical Expertise. 
   The top consultant will propose solutions and strategies to deliver on the investor milestones. They will offer a roadmap to IND readiness, focus on effective resource allocation, and provide flexible engagement models (e.g., part-time, project-based, advisory board roles).

Early CMC consulting is more than problem-solving; it is a proactive investment in predictable timelines, operational efficiency, and market readiness. Founders who embed this expertise into their development strategy are better positioned to navigate complex regulations, secure continued funding, and deliver innovations to patients faster. In a landscape where every day counts, the decision to bring in expert guidance early can define the difference between a stalled asset and a successful launch.